<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Gastric intestinal metaplasia
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Gastric intestinal metaplasia
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Gastric intestinal metaplasia
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Douglas Morgan, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mark Feldman, MD, MACP, AGAF, FACG
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Shilpa Grover, MD, MPH, AGAF
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Mar 30, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2409456">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Globally, gastric cancer is the third leading cause of cancer mortality and the leading cause of infection-associated cancers. Gastric intestinal metaplasia (GIM) is an intermediate precancerous gastric lesion in the gastric cancer cascade of chronic gastritis, atrophic gastritis, intestinal metaplasia (IM), dysplasia, and adenocarcinoma [
         <a href="#rid1">
          1
         </a>
         ]. Although the risk of gastric cancer is increased in patients with GIM, the absolute risk is modest. Specific subsets of patients with GIM may be at higher risk for progression.
        </p>
        <p>
         This topic will review the epidemiology, natural history, diagnosis, and management of distal (noncardia) GIM. Screening for gastric cancer and the management of IM at the gastric cardia (located immediately distal to the squamocolumnar junction and proximal to the oxyntic mucosa) and its distinction from Barrett's esophagus are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2269.html" rel="external">
          "Barrett's esophagus: Epidemiology, clinical manifestations, and diagnosis", section on 'Intestinal metaplasia at GEJ'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2520.html" rel="external">
          "Early gastric cancer: Epidemiology, clinical manifestations, diagnosis, and staging"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16858.html" rel="external">
          "Early gastric cancer: Treatment, natural history, and prognosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2618.html" rel="external">
          "Gastric cancer screening"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2409463">
         <span class="h1">
          TERMINOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         GIM is defined as the replacement of the surface, foveolar, and glandular epithelium in the oxyntic or antral mucosa by intestinal epithelium [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H539680233">
         <span class="h2">
          Classification
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several GIM classification systems are in use [
         <a href="#rid3">
          3-6
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         GIM topographic extent – Based on the extent of gastric involvement on histology, GIM is classified as extensive versus limited [
         <a href="#rid3">
          3,4,7,8
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Extensive IM – GIM involving the corpus and either the antrum and/or incisura angularis. GIM of the corpus alone is also considered a surrogate for extensive metaplasia, as antral metaplasia is usually also present, but may have been missed on biopsy given the patchy distribution.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Limited IM – GIM involving the antrum or incisura.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         GIM histologic subtypes
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Based on the histology with hematoxylin and eosin staining (H&amp;E stain):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Complete IM is defined by the presence of small intestinal-type mucosa with goblet cells that secrete sialomucins, a brush border, and eosinophilic enterocytes  (
         <a class="graphic graphic_picture graphicRef81064" href="/z/d/graphic/81064.html" rel="external">
          picture 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Incomplete IM is defined by the presence of colonic-type epithelium with multiple, irregular mucin droplets of variable size in the cytoplasm and absence of a brush border  (
         <a class="graphic graphic_picture graphicRef77310" href="/z/d/graphic/77310.html" rel="external">
          picture 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Based on mucin expression – IM has also been subtyped based on mucin expression, but its use is mainly limited to research settings. In IM, the original gastric mucins, which have a neutral pH, are replaced by acid mucins, which may be sialic or sulfated. Using a combination Alcian blue and high-iron diamine stain, GIM is classified based on the types of mucins expressed and morphology into the following types [
         <a href="#rid5">
          5
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Type I (complete) IM expresses only sialomucins
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Type II (incomplete) IM expresses a mixture of gastric (neutral) mucins and intestinal sialomucins
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Type III (incomplete) IM expresses sulfomucins
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Combined periodic acid Schiff-AB staining may also be used to discriminate between normal epithelium and IM [
         <a href="#rid9">
          9
         </a>
         ]. It is unclear whether this approach adds to risk stratification beyond the improved identification of incomplete IM [
         <a href="#rid7">
          7
         </a>
         ]. Immunohistochemical stains may also be used for GIM confirmation (eg, MUC2).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Updated Sydney system – The operative link for gastritis assessment (OLGA) and operative link on GIM (OLGIM) staging systems are used to evaluate the severity and extent of atrophy and IM. The severity of gastric atrophy and IM are graded in the antrum/incisura and corpus. OLGA and OLGIM are primarily used in the research setting. Stages III and IV represent more severe extensive disease and correlate with a higher risk of progression  (
         <a class="graphic graphic_table graphicRef121370" href="/z/d/graphic/121370.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef116254" href="/z/d/graphic/116254.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid4">
          4,10,11
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/30.html" rel="external">
          "Metaplastic (chronic) atrophic gastritis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H19264616">
         <span class="h1">
          EPIDEMIOLOGY AND PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Estimates of the global prevalence of GIM vary widely due to the variations in gastric cancer incidence [
         <a href="#rid12">
          12-15
         </a>
         ]. GIM prevalence in high-incidence regions ranges between 19 to 24 percent [
         <a href="#rid12">
          12
         </a>
         ]. In low gastric cancer incidence regions such as the United States and in northern Europe, GIM prevalence is approximately 5 percent [
         <a href="#rid12">
          12
         </a>
         ]. Prevalence of GIM increases with age and is higher in areas with high prevalence of
         <em>
          Helicobacter pylori
         </em>
         (
         <em>
          H. pylori
         </em>
         ),
         <em>
         </em>
         in men, and in current smokers [
         <a href="#rid13">
          13,16-18
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2616.html" rel="external">
          "Epidemiology of gastric cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/119517.html" rel="external">
          "Gastric cancer: Pathology and molecular pathogenesis", section on 'Intestinal metaplasia'
         </a>
         .)
        </p>
        <p>
         GIM is a premalignant stage in the gastric cancer cascade through a series of well-defined and recognizable precursors [
         <a href="#rid19">
          19
         </a>
         ]. The gastric adenocarcinoma multistage model, the "Correa cascade," suggests that a combination of host genetic factors and responses,
         <em>
          H. pylori
         </em>
         genomics, with modulation by dietary and environmental factors, predispose to early pan-gastric mucosal inflammation, which in turn results in gastric atrophy, IM, dysplasia, and adenocarcinoma [
         <a href="#rid20">
          20-22
         </a>
         ]. This model is most applicable to the intestinal subtype of gastric cancer. While there may be reversal of gastric atrophy with
         <em>
          H. pylori
         </em>
         eradication, GIM is considered as a "point of no return" in the multistage model, although this remains an ongoing debate.
        </p>
        <p>
         The metaplastic foci often first appear at the antrum-corpus junction, and frequently at the incisura angularis. As the process advances, the foci enlarge and coalesce, extending to the neighboring mucosa in both the antrum and the corpus [
         <a href="#rid7">
          7
         </a>
         ]. As atrophic and metaplastic glands replace original glands, normal gastric secretions decrease, leading to hypochlorhydria and to low levels of pepsinogen produced by the chief cells of the corpus, and to high circulating levels of gastrin produced by antral G cells. The first metaplastic glands seen in the gastric mucosa phenotypically resemble those of the small intestine, with eosinophilic absorptive enterocytes with a brush border, alternating with mucus-producing goblet cells (complete or small IM). More advanced stages are characterized by phenotypic changes that are similar to colonic mucosa with the glands being lined by irregular goblet cells (incomplete or colonic metaplasia)  (
         <a class="graphic graphic_picture graphicRef81064" href="/z/d/graphic/81064.html" rel="external">
          picture 1
         </a>
         and
         <a class="graphic graphic_picture graphicRef77310" href="/z/d/graphic/77310.html" rel="external">
          picture 2
         </a>
         ). In a subset of patients, foci of dysplasia may develop within areas of IM. (See
         <a class="medical medical_review" href="/z/d/html/119517.html" rel="external">
          "Gastric cancer: Pathology and molecular pathogenesis", section on 'Intestinal versus diffuse types'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1574292">
         <span class="h1">
          CLINICAL FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         GIM in general does not cause specific symptoms and is often found incidentally in patients undergoing upper endoscopy for dyspepsia. However, intestinal metaplasia is associated with gastric hypochlorhydria, which may result in small intestinal bacterial overgrowth with symptoms of bloating, abdominal discomfort, and diarrhea. (See
         <a class="medical medical_review" href="/z/d/html/4776.html" rel="external">
          "Small intestinal bacterial overgrowth: Clinical manifestations and diagnosis", section on 'Clinical features'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2478242570">
         <span class="h1">
          CANCER RISK
         </span>
        </p>
        <p class="headingAnchor" id="H144167845">
         <span class="h2">
          Incidence
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with GIM are thought to be at increased risk for gastric cancer but the absolute risk appears to be low in areas of low gastric cancer incidence, such as North America and northern Europe. A limited number of studies have evaluated the rate of progression to gastric cancer in patients with GIM, and estimates from small studies have varied widely and depend upon the background incidence of gastric cancer [
         <a href="#rid23">
          23-26
         </a>
         ]. In European, Asian, and United States populations, the rates of gastric cancer vary between 1.1 and 2.0 per 1000 person-years, and up to 3.0 per 1000 person-years if high-grade dysplasia is included [
         <a href="#rid11">
          11,25,27-33
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2508553188">
         <span class="h2">
          Risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Risk for gastric cancer may be higher among individuals with incomplete versus complete GIM on histology, extensive versus limited GIM, and those with a family history of gastric cancer in a first-degree relative [
         <a href="#rid11">
          11,26,28,34-37
         </a>
         ]. In a meta-analysis of seven studies, having incomplete versus complete GIM was associated with a threefold increased risk of incident gastric cancer (over 3 to 13 years follow-up; relative risk [RR] 3.3, 95% confidence interval [CI], 1.9-5.6) [
         <a href="#rid38">
          38
         </a>
         ]. Among patients with GIM who had biopsies obtained from both the gastric antrum/incisura and body, extensive GIM versus limited involvement (ie, including involvement of at least the gastric body versus GIM of the antrum and/or incisura, respectively) was associated with a twofold higher pooled RR of incident gastric cancer (RR 2.07, 95% CI, 0.97-4.42). Among patients with GIM, having a family history of a first-degree relative with gastric cancer was associated with 4.5-fold increased risk for incident gastric cancer based on three studies (RR 4.5, 95% CI, 1.3-15.5).
        </p>
        <p>
         Race and ethnicity may also play a role in GIM progression [
         <a href="#rid17">
          17,18,31,32,39
         </a>
         ]. Immigrant populations from high-risk regions to low-incidence regions have a persistent increased risk of gastric cancer [
         <a href="#rid39">
          39
         </a>
         ]. However, data on the influence of other gastric cancer risk factors (eg, smoking and alcohol use, pernicious anemia or autoimmune gastritis,
         <em>
          Helicobacter pylori
         </em>
         infection) on rates of GIM progression are lacking [
         <a href="#rid12">
          12,38
         </a>
         ]. (See
         <a class="local">
          'Management'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1504015926">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of GIM may be suspected based on endoscopic findings, but is established by histology. (See
         <a class="local">
          'Gastric topographic biopsy mapping'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/119517.html" rel="external">
          "Gastric cancer: Pathology and molecular pathogenesis", section on 'Intestinal metaplasia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1984120904">
         <span class="h2">
          Upper endoscopy with biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Endoscopically, GIM has the appearance of small grey-white, slightly elevated plaques surrounded by mixed patchy pink and pale areas of mucosa causing an irregular, uneven surface. GIM may also have the appearance of mottled patchy erythema. High-quality endoscopy examination is needed to detect GIM. We perform upper endoscopy with high-resolution scopes and use enhanced imaging with narrow band imaging (NBI) when GIM is suspected. NBI is a high-resolution endoscopic technique that enhances the fine structure of the mucosal surface without the use of dyes. NBI should be combined with magnification endoscopy to improve visualization of surface and vascular patterns for GIM detection. The light blue crest pattern and/or marginal turbid band are suggestive of GIM [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
         Other endoscopic measures that may increase the yield of upper endoscopy include adequate examination time (seven minutes intubation to extubation), mucosal cleaning, and air insufflation for mucosal visualization [
         <a href="#rid41">
          41-43
         </a>
         ]. Visual inspection of the stomach should be accompanied by photographic documentation (antrum, pylorus, incisura, lesser curve, greater curve, fundus, and cardia) and gastric biopsy mapping [
         <a href="#rid44">
          44,45
         </a>
         ]. Other station-based screening protocols (with 22 or 26 pictures) have also been proposed whereby each area of the stomach is viewed and photographed [
         <a href="#rid44">
          44,46
         </a>
         ].
        </p>
        <p>
         Several studies have demonstrated that white light endoscopy alone (without high-resolution or enhanced imaging) has low sensitivity for GIM and cannot accurately distinguish between nonatrophic gastritis, multifocal atrophic gastritis, and IM [
         <a href="#rid47">
          47-49
         </a>
         ]. In addition, interobserver variability often limits the utility of endoscopic findings [
         <a href="#rid50">
          50
         </a>
         ]. As compared with histology, NBI with magnification endoscopy has a sensitivity and specificity of 89 and 93 percent, respectively [
         <a href="#rid40">
          40,51-55
         </a>
         ]. Further studies are needed to validate NBI patterns in GIM [
         <a href="#rid56">
          56-60
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2646.html" rel="external">
          "Magnification endoscopy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2650.html" rel="external">
          "Barrett's esophagus: Evaluation with optical chromoscopy", section on 'Principles'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5283615">
         <span class="h3">
          Gastric topographic biopsy mapping
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diagnostic findings of GIM on gastric biopsy include replacement of the surface, foveolar, and glandular epithelium in the oxyntic and/or antral mucosa by metaplastic epithelium. However, gastric topographic mapping is required to determine the type and extent of metaplasia and guide management  (
         <a class="graphic graphic_algorithm graphicRef127117" href="/z/d/graphic/127117.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid7">
          7,9,24
         </a>
         ]. For gastric topographic mapping, biopsies are obtained from a minimum of five nontargeted biopsy sites (the lesser and greater curvatures of both the antrum and corpus, and the incisura angularis), with one or two biopsies ("bites") per site  (
         <a class="graphic graphic_figure graphicRef127130" href="/z/d/graphic/127130.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid3">
          3
         </a>
         ]. Specimens should be placed in a minimum of two bottles, for the corpus and antrum with incisura, respectively [
         <a href="#rid61">
          61-67
         </a>
         ]. In addition, targeted biopsies should be obtained from irregular areas of the mucosa to rule out dysplasia and early gastric cancer. Pathology reports should include comments on the GIM subtypes, which are routine with H&amp;E staining. (See
         <a class="local">
          'Terminology'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2077930530">
         <span class="h2">
          Tests with unclear role
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other endoscopic modalities
         </strong>
         – Several other endoscopic modalities have been evaluated to detect early gastric cancer and other gastric precancerous lesions, and endoscopy imaging technologies are in rapid evolution [
         <a href="#rid68">
          68,69
         </a>
         ]. However, further studies are needed before they can be routinely recommended [
         <a href="#rid70">
          70-72
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Magnification chromoendoscopy – The use of magnification chromoendoscopy for GIM and early gastric cancer is limited to specialized centers, primarily in Asia. Magnification chromoendoscopy involves the topical application of stains or pigments to improve tissue localization, characterization, or diagnosis with magnification endoscopy. Although several agents (eg,
         <a class="drug drug_general" data-topicid="9636" href="/z/d/drug information/9636.html" rel="external">
          methylene blue
         </a>
         , acetic acid) have been studied,
         <a class="drug drug_general" data-topicid="9088" href="/z/d/drug information/9088.html" rel="external">
          indigo carmine
         </a>
         is the most commonly used stain [
         <a href="#rid73">
          73,74
         </a>
         ]. Magnification chromoendoscopy requires specialized training and lengthens the procedure duration. While some studies have demonstrated a significant improvement in detection of GIM with the use of chromoendoscopy with indigo carmine, discordant data have also been published. (See
         <a class="medical medical_review" href="/z/d/html/2670.html" rel="external">
          "Chromoendoscopy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2646.html" rel="external">
          "Magnification endoscopy", section on 'Stomach'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Confocal endomicroscopy – Confocal endomicroscopy is based upon the principle of illuminating a tissue with a low-power laser and then detecting fluorescent light reflected from the tissue. The laser is focused at a specific depth and only light reflected back from that plane is refocused and able to pass through the pinhole confocal aperture. As a result, scattered light from above and below the plane of interest is not detected, increasing spatial resolution. The area being examined is scanned in the horizontal and vertical planes and an image is reconstructed. The applications and efficacy of confocal microscopy are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/13923.html" rel="external">
          "Confocal laser endomicroscopy and endocytoscopy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Biomarkers
         </strong>
         – Serum pepsinogen I and the pepsinogen I/II ratio have been studied extensively as a screening modality for gastric atrophy, GIM, dysplasia, and adenocarcinoma in Asian and European populations [
         <a href="#rid75">
          75-77
         </a>
         ]. The testing has been combined with the
         <em>
          Helicobacter pylori
         </em>
         serology and/or Gastrin 17 in some protocols [
         <a href="#rid78">
          78-80
         </a>
         ]. The limited sensitivity and specificity of pepsinogen and related assays testing preclude its use. (See
         <a class="medical medical_review" href="/z/d/html/2618.html" rel="external">
          "Gastric cancer screening", section on 'Serum pepsinogen'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1456761026">
         <span class="h1">
          POST-DIAGNOSTIC EVALUATION
         </span>
        </p>
        <p class="headingAnchor" id="H248157626">
         <span class="h2">
          Assessment of cancer risk
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with GIM are considered at high-risk for gastric cancer if they have any one of the following [
         <a href="#rid39">
          39,41,81-83
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Family history of gastric cancer in a first-degree relative
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Incomplete GIM
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Extensive or corpus GIM
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Racial/ethnic minorities and/or immigrants from high-incidence areas
        </p>
        <p>
        </p>
        <p>
         Determining the type and extent of GIM requires gastric topographic mapping  (
         <a class="graphic graphic_algorithm graphicRef127117" href="/z/d/graphic/127117.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid7">
          7,9,24
         </a>
         ]. If GIM is suspected on the index upper endoscopy, biopsy mapping may be performed. However, if GIM is discovered incidentally on a gastric biopsy but without complete biopsy mapping, the decision to perform a repeat upper endoscopy and the timing of the procedure is based on risk factors for gastric adenocarcinoma (eg, family history of gastric cancer, racial/ethnic minorities, and/or immigrants from high-incidence areas). (See
         <a class="local">
          'Endoscopic surveillance in selected patients'
         </a>
         below and
         <a class="local">
          'Gastric topographic biopsy mapping'
         </a>
         above.)
        </p>
        <p>
         Assessment of family cancer history is important in determining cancer risk and should include a cancer history in first- and second-degree relatives. Familial clustering of gastric cancer occurs in approximately 10 percent of cases. However, hereditary gastric cancer syndromes account for approximately 1 to 3 percent of cases and include three main subgroups: hereditary diffuse gastric cancer, familial intestinal gastric cancer, and other single-gene syndromes associated with an increased risk of gastric adenocarcinoma (eg, Lynch syndrome, Cowden syndrome, Peutz Jegher syndrome, familial adenomatous polyposis).
        </p>
        <p>
         Individuals with any one of the following should be referred for genetic evaluation for a hereditary gastric cancer syndrome:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gastric cancer in one family member before age 40
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gastric cancer in two first-degree/second-degree relatives with one diagnosis before age 50
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gastric cancer in three first-degree/second-degree relatives independent of age
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1447433797">
         <span class="h2">
          Screening for Helicobacter pylori (H. pylori)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infection with
         <em>
          H. pylori
         </em>
         is initially assessed by the histologic evaluation of gastric biopsy samples [
         <a href="#rid84">
          84
         </a>
         ]. However, if the histology does not demonstrate evidence of
         <em>
          H. pylori
         </em>
         , noninvasive testing with serology should be performed.
         <em>
          H. pylori
         </em>
         organism loads may decrease with the onset of precancerous lesions and adenocarcinoma, thereby reducing biopsy sensitivity. In the event of negative biopsies for
         <em>
          H. pylori
         </em>
         , infection status should be determined with serology. Any patient with positive serology who does not have a definitive history of having been treated for
         <em>
          H. pylori
         </em>
         should receive treatment, even if biopsies are negative. (See
         <a class="medical medical_review" href="/z/d/html/18.html" rel="external">
          "Indications and diagnostic tests for Helicobacter pylori infection in adults", section on 'Noninvasive testing'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7.html" rel="external">
          "Treatment regimens for Helicobacter pylori in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H458221841">
         <span class="h1">
          MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H3512913">
         <span class="h2">
          General measures in all patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         General measures to decrease the risk of gastric cancer include smoking cessation, moderation of alcohol intake, and eradication of
         <em>
          Helicobacter pylori
         </em>
         (
         <em>
          H. pylori
         </em>
         ).
         <em>
          H. pylori
         </em>
         is a known risk factor for gastric cancer [
         <a href="#rid24">
          24
         </a>
         ]. Eradication of
         <em>
          H. pylori
         </em>
         appears to reverse the histologic changes in the majority of patients with chronic nonatrophic gastritis and in many patients with multifocal atrophic gastritis, but it is less conclusive for those with GIM [
         <a href="#rid85">
          85-88
         </a>
         ]. Although eradication therapy does not reverse GIM, it may slow the progression to gastric cancer [
         <a href="#rid86">
          86,89
         </a>
         ]. Persistent infection and/or reinfection appears to affect the risk of progression [
         <a href="#rid90">
          90
         </a>
         ]. In patients with GIM who have undergone endoscopic treatment for early gastric cancer or surgical resection for a gastric adenocarcinoma, eradication has been shown to decrease the risk of future adenocarcinoma [
         <a href="#rid91">
          91,92
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16858.html" rel="external">
          "Early gastric cancer: Treatment, natural history, and prognosis", section on 'Helicobacter pylori infection'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5283746">
         <span class="h2">
          Endoscopic surveillance in selected patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         In individuals with high-risk GIM, we suggest surveillance upper endoscopy which includes a detailed visual inspection, narrow band imaging if there is local expertise, and gastric biopsy mapping  (
         <a class="graphic graphic_algorithm graphicRef127117" href="/z/d/graphic/127117.html" rel="external">
          algorithm 1
         </a>
         ). High-risk GIM groups include patients with any one of the following [
         <a href="#rid39">
          39,41,81-83
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Family history of gastric cancer in a first-degree relative
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Incomplete GIM
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Extensive or corpus GIM
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Racial/ethnic minorities in the United States (including African Americans, Hispanics, and Asians)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         First-generation immigrants from high-incidence areas (eg, Eastern Asia, mountainous Latin America)
        </p>
        <p>
        </p>
        <p>
         Evidence suggests that surveillance may lead to early detection of gastric cancer and improved survival [
         <a href="#rid11">
          11,93-95
         </a>
         ]. However, prospective studies are needed to determine the optimal surveillance intervals. Our recommendations for surveillance, depending on the type and extent of IM, are based on expert opinion and are largely consistent with other guidelines [
         <a href="#rid41">
          41,81,82
         </a>
         ]. The role of surveillance and management of gastric cancer risk in patients with hereditary gastric cancer syndromes is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2511.html" rel="external">
          "Hereditary diffuse gastric cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14255.html" rel="external">
          "Li-Fraumeni syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2605.html" rel="external">
          "Lynch syndrome (hereditary nonpolyposis colorectal cancer): Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2593.html" rel="external">
          "Clinical manifestations and diagnosis of familial adenomatous polyposis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/785.html" rel="external">
          "Overview of hereditary breast and ovarian cancer syndromes"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1167369522">
         <span class="h3">
          Extensive or incomplete IM
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with extensive IM or incomplete IM, we perform endoscopic surveillance for gastric cancer at the three-year interval [
         <a href="#rid96">
          96,97
         </a>
         ]. Although other guidelines have suggested that those with a family history and extensive or incomplete IM undergo more intense (one to two year) surveillance endoscopy, and evidence to support this recommendation are lacking [
         <a href="#rid81">
          81
         </a>
         ]. (See
         <a class="local">
          'Upper endoscopy with biopsy'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H976024393">
         <span class="h3">
          Limited or complete GIM and additional gastric cancer risk factor
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with limited or complete GIM and a risk factor for gastric cancer (eg, family history of gastric cancer in a first-degree relative [without a hereditary gastric cancer syndrome], persistent
         <em>
          H. pylori
         </em>
         gastritis, pernicious anemia), we suggest endoscopic surveillance for gastric cancer every three years. In patients with limited or complete GIM who do not have additional risk factors for gastric cancer, evidence to support routine endoscopic surveillance are lacking [
         <a href="#rid41">
          41,81,82
         </a>
         ]. However, GIM surveillance should be driven by shared patient-physician decision making.
        </p>
        <p class="headingAnchor" id="H2409585">
         <span class="h2">
          Unclear role of chemoprevention
         </span>
         <span class="headingEndMark">
          —
         </span>
         Definitive evidence to support the use of chemoprevention agents in patients with GIM is lacking. Although observational studies have suggested a benefit of
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         , nonsteroidal anti-inflammatory drugs, and cyclo-oxygenase-2 inhibitors in decreasing the risk of gastric cancer as well as the regression of IM with
         <a class="drug drug_general" data-topicid="8847" href="/z/d/drug information/8847.html" rel="external">
          celecoxib
         </a>
         use, there are no randomized controlled trials [
         <a href="#rid98">
          98-102
         </a>
         ]. In addition, studies that have evaluated the effect of antioxidant vitamin supplementation (eg, ascorbic acid,
         <a class="drug drug_general" data-topicid="9127" href="/z/d/drug information/9127.html" rel="external">
          beta-carotene
         </a>
         ) on the risk of progression of gastric precancerous lesions have yielded inconsistent results [
         <a href="#rid103">
          103-107
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1497689493">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/131407.html" rel="external">
          "Society guideline links: Gastric intestinal metaplasia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2409592">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         GIM is characterized by the replacement of the surface, foveolar, and glandular epithelium in the oxyntic or antral mucosa by intestinal epithelium. (See
         <a class="local">
          'Terminology'
         </a>
         above and
         <a class="local">
          'Classification'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         GIM is an important premalignant stage in the gastric cancer cascade through a series of well-defined and recognizable precursors. The gastric adenocarcinoma multistage model, the "Correa cascade," suggests that a combination of host genetic factors and responses,
         <em>
          Helicobacter pylori
         </em>
         (
         <em>
          H. pylori
         </em>
         ) genomics, with modulation by dietary and environmental factors, predispose to early pan-gastric mucosal inflammation, which in turn results in gastric atrophy, IM, dysplasia, and adenocarcinoma. (See
         <a class="local">
          'Epidemiology and pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with GIM are thought to be at increased risk for gastric cancer but the absolute risk appears to be modest in areas of low gastric cancer incidence (2.5 per 1000 person-years). However, among patients with GIM, the risk of gastric cancer is higher in individuals with extensive and incomplete IM. (See
         <a class="local">
          'Cancer risk'
         </a>
         above and
         <a class="local">
          'Classification'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         GIM in general does not cause specific symptoms and is often diagnosed incidentally in patients undergoing upper endoscopy for dyspepsia. However, it is associated with gastric hypochlorhydria, which may result in small intestinal bacterial overgrowth with symptoms of bloating, abdominal discomfort, and diarrhea. On upper endoscopy, GIM has a nonspecific appearance and involved mucosa may have rough or villous appearance, or may be seen as thin, white mucosal deposits. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The diagnosis of GIM may be suspected based on endoscopic findings, but is established by histology. High-quality endoscopy examination is needed to improve detection. We perform upper endoscopy with narrow band imaging (NBI) and biopsy mapping  (
         <a class="graphic graphic_figure graphicRef127130" href="/z/d/graphic/127130.html" rel="external">
          figure 1
         </a>
         ). (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with GIM are considered at increased risk for gastric cancer if they have any one of the following (see
         <a class="local">
          'Classification'
         </a>
         above and
         <a class="local">
          'Assessment of cancer risk'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Family history of gastric cancer in a first-degree relative
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Incomplete GIM
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Extensive or corpus GIM
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Racial/ethnic minorities in the United States (including African Americans, Hispanics, and Asians)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         First-generation immigrants from high-incidence areas (eg, Eastern Asia, mountainous Latin America)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Determining the type and extent of GIM requires gastric topographic mapping  (
         <a class="graphic graphic_figure graphicRef127130" href="/z/d/graphic/127130.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         General measures to decrease the risk of GIM progression to gastric cancer include smoking cessation, moderation of alcohol intake, and eradication of
         <em>
          H. pylori
         </em>
         . Although eradication of
         <em>
          H. pylori
         </em>
         does not reverse GIM, it may slow progression to gastric cancer. (See
         <a class="local">
          'General measures in all patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In individuals with high-risk GIM, we perform surveillance upper endoscopy at the three-year interval  (
         <a class="graphic graphic_algorithm graphicRef127117" href="/z/d/graphic/127117.html" rel="external">
          algorithm 1
         </a>
         ). Surveillance endoscopic evaluation includes a detailed visual inspection with high-resolution endoscopes, NBI if there is local expertise, and gastric biopsy mapping. (See
         <a class="local">
          'Management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3446948179">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Pelayo Correa, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Correa P. The biological model of gastric carcinogenesis. IARC Sci Publ 2004; :301.
          </a>
         </li>
         <li class="breakAll">
          Antonioli DA. Gastric carcinoma and its precursors. In: Gastrointestinal Pathology, Goldman H, Appelman HD, Kaufman N (Eds), United States and Canadian Academy of Pathology Monograph in Pathology No. 31, Williams &amp; Wilkins, Baltimore 1990. p.144.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20:1161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Capelle LG, de Vries AC, Haringsma J, et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc 2010; 71:1150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Filipe MI, Muñoz N, Matko I, et al. Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. Int J Cancer 1994; 57:324.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldenring JR, Nam KT, Wang TC, et al. Spasmolytic polypeptide-expressing metaplasia and intestinal metaplasia: time for reevaluation of metaplasias and the origins of gastric cancer. Gastroenterology 2010; 138:2207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Correa P, Piazuelo MB, Wilson KT. Pathology of gastric intestinal metaplasia: clinical implications. Am J Gastroenterol 2010; 105:493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Vries AC, Haringsma J, de Vries RA, et al. The use of clinical, histologic, and serologic parameters to predict the intragastric extent of intestinal metaplasia: a recommendation for routine practice. Gastrointest Endosc 2009; 70:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           González CA, Sanz-Anquela JM, Gisbert JP, et al. Utility of subtyping intestinal metaplasia as marker of gastric cancer risk. A review of the evidence. Int J Cancer 2013; 133:1023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rugge M, Correa P, Di Mario F, et al. OLGA staging for gastritis: a tutorial. Dig Liver Dis 2008; 40:650.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           den Hollander WJ, Holster IL, den Hoed CM, et al. Surveillance of premalignant gastric lesions: a multicentre prospective cohort study from low incidence regions. Gut 2019; 68:585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Altayar O, Davitkov P, Shah SC, et al. AGA Technical Review on Gastric Intestinal Metaplasia-Epidemiology and Risk Factors. Gastroenterology 2020; 158:732.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fennerty MB, Emerson JC, Sampliner RE, et al. Gastric intestinal metaplasia in ethnic groups in the southwestern United States. Cancer Epidemiol Biomarkers Prev 1992; 1:293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           den Hoed CM, van Eijck BC, Capelle LG, et al. The prevalence of premalignant gastric lesions in asymptomatic patients: predicting the future incidence of gastric cancer. Eur J Cancer 2011; 47:1211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sipponen P, Kimura K. Intestinal metaplasia, atrophic gastritis and stomach cancer: trends over time. Eur J Gastroenterol Hepatol 1994; 6 Suppl 1:S79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sonnenberg A, Genta RM. Changes in the Gastric Mucosa With Aging. Clin Gastroenterol Hepatol 2015; 13:2276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang RJ, Ende AR, Singla A, et al. Prevalence, risk factors, and surveillance patterns for gastric intestinal metaplasia among patients undergoing upper endoscopy with biopsy. Gastrointest Endosc 2020; 91:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan MC, Mallepally N, Liu Y, et al. Demographic and Lifestyle Risk Factors for Gastric Intestinal Metaplasia Among US Veterans. Am J Gastroenterol 2020; 115:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Correa P, Haenszel W, Cuello C, et al. A model for gastric cancer epidemiology. Lancet 1975; 2:58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Polk DB, Peek RM Jr. Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer 2010; 10:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Correa P, Malcom G, Schmidt B, et al. Review article: Antioxidant micronutrients and gastric cancer. Aliment Pharmacol Ther 1998; 12 Suppl 1:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amieva M, Peek RM Jr. Pathobiology of Helicobacter pylori-Induced Gastric Cancer. Gastroenterology 2016; 150:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Correa P, Haenszel W, Cuello C, et al. Gastric precancerous process in a high risk population: cohort follow-up. Cancer Res 1990; 50:4737.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dinis-Ribeiro M, Areia M, de Vries AC, et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 2012; 44:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Vries AC, van Grieken NC, Looman CW, et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology 2008; 134:945.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           González CA, Pardo ML, Liso JM, et al. Gastric cancer occurrence in preneoplastic lesions: a long-term follow-up in a high-risk area in Spain. Int J Cancer 2010; 127:2654.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Song H, Ekheden IG, Zheng Z, et al. Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk Western population. BMJ 2015; 351:h3867.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           González CA, Sanz-Anquela JM, Companioni O, et al. Incomplete type of intestinal metaplasia has the highest risk to progress to gastric cancer: results of the Spanish follow-up multicenter study. J Gastroenterol Hepatol 2016; 31:953.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Plummer M, van Doorn LJ, Franceschi S, et al. Helicobacter pylori cytotoxin-associated genotype and gastric precancerous lesions. J Natl Cancer Inst 2007; 99:1328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim N, Park RY, Cho SI, et al. Helicobacter pylori infection and development of gastric cancer in Korea: long-term follow-up. J Clin Gastroenterol 2008; 42:448.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reddy KM, Chang JI, Shi JM, Wu BU. Risk of Gastric Cancer Among Patients With Intestinal Metaplasia of the Stomach in a US Integrated Health Care System. Clin Gastroenterol Hepatol 2016; 14:1420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li D, Bautista MC, Jiang SF, et al. Risks and Predictors of Gastric Adenocarcinoma in Patients with Gastric Intestinal Metaplasia and Dysplasia: A Population-Based Study. Am J Gastroenterol 2016; 111:1104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee TY, Wang RC, Lee YC, et al. The Incidence of Gastric Adenocarcinoma Among Patients With Gastric Intestinal Metaplasia: A Long-term Cohort Study. J Clin Gastroenterol 2016; 50:532.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sossai P, Barbazza R. Intestinal metaplasia and dysplasia in gastric ulcer and its tissue repair. Am J Gastroenterol 1990; 85:829.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silva S, Filipe MI, Pinho A. Variants of intestinal metaplasia in the evolution of chronic atrophic gastritis and gastric ulcer. A follow up study. Gut 1990; 31:1097.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fang DC, Liu WW. Subtypes of intestinal metaplasia and gastric carcinoma. A clinicoendoscopic follow-up of 112 cases. Chin Med J (Engl) 1991; 104:467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shichijo S, Hirata Y, Niikura R, et al. Histologic intestinal metaplasia and endoscopic atrophy are predictors of gastric cancer development after Helicobacter pylori eradication. Gastrointest Endosc 2016; 84:618.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gawron AJ, Shah SC, Altayar O, et al. AGA Technical Review on Gastric Intestinal Metaplasia-Natural History and Clinical Outcomes. Gastroenterology 2020; 158:705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pabla BS, Shah SC, Corral JE, Morgan DR. Increased Incidence and Mortality of Gastric Cancer in Immigrant Populations from High to Low Regions of Incidence: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol 2020; 18:347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uedo N, Ishihara R, Iishi H, et al. A new method of diagnosing gastric intestinal metaplasia: narrow-band imaging with magnifying endoscopy. Endoscopy 2006; 38:819.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta S, Li D, El Serag HB, et al. AGA Clinical Practice Guidelines on Management of Gastric Intestinal Metaplasia. Gastroenterology 2020; 158:693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Emura F, Sharma P, Arantes V, et al. Principles and practice to facilitate complete photodocumentation of the upper gastrointestinal tract: World Endoscopy Organization position statement. Dig Endosc 2020; 32:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mier PD, van den Hurk JJ. Lysosomal hydrolases of the epidermis. I. Glycosidases. Br J Dermatol 1975; 93:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Emura F, Rodriguez-Reyes C, Giraldo-Cadavid L. Early Gastric Cancer: Current Limitations and What Can Be Done to Address Them. Am J Gastroenterol 2019; 114:841.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Machaca Quea NR, Emura F, Barreda Bolaños F, et al. Effectiveness of systematic alphanumeric coded endoscopy for diagnosis of gastric intraepithelial neoplasia in a low socioeconomic population. Endosc Int Open 2016; 4:E1083.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yao K. The endoscopic diagnosis of early gastric cancer. Ann Gastroenterol 2013; 26:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stathopoulos G, Goldberg RD, Blackstone MO. Endoscopic diagnosis of intestinal metaplasia. Gastrointest Endosc 1990; 36:544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carpenter HA, Talley NJ. Gastroscopy is incomplete without biopsy: clinical relevance of distinguishing gastropathy from gastritis. Gastroenterology 1995; 108:917.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Redéen S, Petersson F, Jönsson KA, Borch K. Relationship of gastroscopic features to histological findings in gastritis and Helicobacter pylori infection in a general population sample. Endoscopy 2003; 35:946.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laine L, Cohen H, Sloane R, et al. Interobserver agreement and predictive value of endoscopic findings for H. pylori and gastritis in normal volunteers. Gastrointest Endosc 1995; 42:420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gonen C, Simsek I, Sarioglu S, Akpinar H. Comparison of high resolution magnifying endoscopy and standard videoendoscopy for the diagnosis of Helicobacter pylori gastritis in routine clinical practice: a prospective study. Helicobacter 2009; 14:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anagnostopoulos GK, Yao K, Kaye P, et al. High-resolution magnification endoscopy can reliably identify normal gastric mucosa, Helicobacter pylori-associated gastritis, and gastric atrophy. Endoscopy 2007; 39:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tahara T, Shibata T, Nakamura M, et al. Gastric mucosal pattern by using magnifying narrow-band imaging endoscopy clearly distinguishes histological and serological severity of chronic gastritis. Gastrointest Endosc 2009; 70:246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kato M, Kaise M, Yonezawa J, et al. Magnifying endoscopy with narrow-band imaging achieves superior accuracy in the differential diagnosis of superficial gastric lesions identified with white-light endoscopy: a prospective study. Gastrointest Endosc 2010; 72:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Capelle LG, Haringsma J, de Vries AC, et al. Narrow band imaging for the detection of gastric intestinal metaplasia and dysplasia during surveillance endoscopy. Dig Dis Sci 2010; 55:3442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sobrino-Cossío S, Abdo Francis JM, Emura F, et al. Efficacy of narrow-band imaging for detecting intestinal metaplasia in adult patients with symptoms of dyspepsia. Rev Gastroenterol Mex (Engl Ed) 2018; 83:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Esposito G, Pimentel-Nunes P, Angeletti S, et al. Endoscopic grading of gastric intestinal metaplasia (EGGIM): a multicenter validation study. Endoscopy 2019; 51:515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buxbaum JL, Hormozdi D, Dinis-Ribeiro M, et al. Narrow-band imaging versus white light versus mapping biopsy for gastric intestinal metaplasia: a prospective blinded trial. Gastrointest Endosc 2017; 86:857.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pimentel-Nunes P, Dinis-Ribeiro M, Soares JB, et al. A multicenter validation of an endoscopic classification with narrow band imaging for gastric precancerous and cancerous lesions. Endoscopy 2012; 44:236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Savarino E, Corbo M, Dulbecco P, et al. Narrow-band imaging with magnifying endoscopy is accurate for detecting gastric intestinal metaplasia. World J Gastroenterol 2013; 19:2668.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El-Zimaity HM, Graham DY. Evaluation of gastric mucosal biopsy site and number for identification of Helicobacter pylori or intestinal metaplasia: role of the Sydney System. Hum Pathol 1999; 30:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guarner J, Herrera-Goepfert R, Mohar A, et al. Diagnostic yield of gastric biopsy specimens when screening for preneoplastic lesions. Hum Pathol 2003; 34:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eriksson NK, Färkkilä MA, Voutilainen ME, Arkkila PE. The clinical value of taking routine biopsies from the incisura angularis during gastroscopy. Endoscopy 2005; 37:532.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Vries AC, Haringsma J, de Vries RA, et al. Biopsy strategies for endoscopic surveillance of pre-malignant gastric lesions. Helicobacter 2010; 15:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rugge M, Farinati F, Di Mario F, et al. Gastric epithelial dysplasia: a prospective multicenter follow-up study from the Interdisciplinary Group on Gastric Epithelial Dysplasia. Hum Pathol 1991; 22:1002.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Satoh K, Kimura K, Taniguchi Y, et al. Biopsy sites suitable for the diagnosis of Helicobacter pylori infection and the assessment of the extent of atrophic gastritis. Am J Gastroenterol 1998; 93:569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodríguez-Carrasco M, Libânio D, Dinis-Ribeiro M, Pimentel-Nunes P. Where should gastric biopsies be performed when areas of intestinal metaplasia are observed? Endosc Int Open 2019; 7:E1636.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shinozaki S, Osawa H, Hayashi Y, et al. Linked color imaging for the detection of early gastrointestinal neoplasms. Therap Adv Gastroenterol 2019; 12:1756284819885246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castro R, Rodriguez M, Libânio D, et al. Reliability and accuracy of blue light imaging for staging of intestinal metaplasia in the stomach. Scand J Gastroenterol 2019; 54:1301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Subramanian V, Ragunath K. Advanced endoscopic imaging: a review of commercially available technologies. Clin Gastroenterol Hepatol 2014; 12:368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bok GH, Jeon SR, Cho JY, et al. The accuracy of probe-based confocal endomicroscopy versus conventional endoscopic biopsies for the diagnosis of superficial gastric neoplasia (with videos). Gastrointest Endosc 2013; 77:899.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pittayanon R, Rerknimitr R. Role of digital chromoendoscopy and confocal laser endomicroscopy for gastric intestinal metaplasia and cancer surveillance. World J Gastrointest Endosc 2012; 4:472.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dinis-Ribeiro M, da Costa-Pereira A, Lopes C, et al. Magnification chromoendoscopy for the diagnosis of gastric intestinal metaplasia and dysplasia. Gastrointest Endosc 2003; 57:498.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Areia M, Amaro P, Dinis-Ribeiro M, et al. External validation of a classification for methylene blue magnification chromoendoscopy in premalignant gastric lesions. Gastrointest Endosc 2008; 67:1011.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dinis-Ribeiro M, Yamaki G, Miki K, et al. Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. J Med Screen 2004; 11:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang YK, Yu JC, Kang WM, et al. Significance of Serum Pepsinogens as a Biomarker for Gastric Cancer and Atrophic Gastritis Screening: A Systematic Review and Meta-Analysis. PLoS One 2015; 10:e0142080.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Terasawa T, Nishida H, Kato K, et al. Prediction of gastric cancer development by serum pepsinogen test and Helicobacter pylori seropositivity in Eastern Asians: a systematic review and meta-analysis. PLoS One 2014; 9:e109783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamaguchi Y, Nagata Y, Hiratsuka R, et al. Gastric Cancer Screening by Combined Assay for Serum Anti-Helicobacter pylori IgG Antibody and Serum Pepsinogen Levels--The ABC Method. Digestion 2016; 93:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ikeda F, Shikata K, Hata J, et al. Combination of Helicobacter pylori Antibody and Serum Pepsinogen as a Good Predictive Tool of Gastric Cancer Incidence: 20-Year Prospective Data From the Hisayama Study. J Epidemiol 2016; 26:629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zagari RM, Rabitti S, Greenwood DC, et al. Systematic review with meta-analysis: diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis. Aliment Pharmacol Ther 2017; 46:657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pimentel-Nunes P, Libânio D, Marcos-Pinto R, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy 2019; 51:365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Banks M, Graham D, Jansen M, et al. British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. Gut 2019; 68:1545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah SC, Gawron AJ, Mustafa RA, Piazuelo MB. Histologic Subtyping of Gastric Intestinal Metaplasia: Overview and Considerations for Clinical Practice. Gastroenterology 2020; 158:745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hung KW, Maratt JK, Cho WK, et al. AGA Institute Quality Measure Development for the Management of Gastric Intestinal Metaplasia With Helicobacter pylori. Gastroenterology 2022; 163:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pimanov SI, Makarenko EV, Voropaeva AV, et al. Helicobacter pylori eradication improves gastric histology and decreases serum gastrin, pepsinogen I and pepsinogen II levels in patients with duodenal ulcer. J Gastroenterol Hepatol 2008; 23:1666.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rokkas T, Pistiolas D, Sechopoulos P, et al. The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis. Helicobacter 2007; 12 Suppl 2:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watari J, Das KK, Amenta PS, et al. Effect of eradication of Helicobacter pylori on the histology and cellular phenotype of gastric intestinal metaplasia. Clin Gastroenterol Hepatol 2008; 6:409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ford AC, Forman D, Hunt R, et al. Helicobacter pylori eradication for the prevention of gastric neoplasia. Cochrane Database Syst Rev 2015; 2015:CD005583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang J, Xu L, Shi R, et al. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis. Digestion 2011; 83:253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mera RM, Bravo LE, Camargo MC, et al. Dynamics of Helicobacter pylori infection as a determinant of progression of gastric precancerous lesions: 16-year follow-up of an eradication trial. Gut 2018; 67:1239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008; 372:392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi IJ, Kook MC, Kim YI, et al. Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer. N Engl J Med 2018; 378:1085.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whiting JL, Sigurdsson A, Rowlands DC, et al. The long term results of endoscopic surveillance of premalignant gastric lesions. Gut 2002; 50:378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rokkas T, Filipe MI, Sladen GE. Detection of an increased incidence of early gastric cancer in patients with intestinal metaplasia type III who are closely followed up. Gut 1991; 32:1110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Connor A, McNamara D, O'Moráin CA. Surveillance of gastric intestinal metaplasia for the prevention of gastric cancer. Cochrane Database Syst Rev 2013; :CD009322.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pimenta-Melo AR, Monteiro-Soares M, Libânio D, Dinis-Ribeiro M. Missing rate for gastric cancer during upper gastrointestinal endoscopy: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2016; 28:1041.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teh JL, Tan JR, Lau LJ, et al. Longer examination time improves detection of gastric cancer during diagnostic upper gastrointestinal endoscopy. Clin Gastroenterol Hepatol 2015; 13:480.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tian W, Zhao Y, Liu S, Li X. Meta-analysis on the relationship between nonsteroidal anti-inflammatory drug use and gastric cancer. Eur J Cancer Prev 2010; 19:288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang WH, Huang JQ, Zheng GF, et al. Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2003; 95:1784.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang HB, Cheng HC, Sheu BS, et al. Chronic celecoxib users more often show regression of gastric intestinal metaplasia after Helicobacter pylori eradication. Aliment Pharmacol Ther 2007; 25:455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hung KH, Yang HB, Cheng HC, et al. Short-term celecoxib to regress long-term persistent gastric intestinal metaplasia after Helicobacter pylori eradication. J Gastroenterol Hepatol 2010; 25:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang LJ, Wang SY, Huo XH, et al. Anti-Helicobacter pylori therapy followed by celecoxib on progression of gastric precancerous lesions. World J Gastroenterol 2009; 15:2731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mera R, Fontham ET, Bravo LE, et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut 2005; 54:1536.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leung WK, Ng EK, Chan FK, et al. Effects of long-term rofecoxib on gastric intestinal metaplasia: results of a randomized controlled trial. Clin Cancer Res 2006; 12:4766.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Plummer M, Vivas J, Lopez G, et al. Chemoprevention of precancerous gastric lesions with antioxidant vitamin supplementation: a randomized trial in a high-risk population. J Natl Cancer Inst 2007; 99:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           You WC, Brown LM, Zhang L, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst 2006; 98:974.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Correa P, Fontham ET, Bravo JC, et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-helicobacter pylori therapy. J Natl Cancer Inst 2000; 92:1881.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 16636 Version 16.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15055303" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The biological model of gastric carcinogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15055303" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The biological model of gastric carcinogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8827022" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20381801" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8168991" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20450866" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Spasmolytic polypeptide-expressing metaplasia and intestinal metaplasia: time for reevaluation of metaplasias and the origins of gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20203636" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Pathology of gastric intestinal metaplasia: clinical implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19249770" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The use of clinical, histologic, and serologic parameters to predict the intragastric extent of intestinal metaplasia: a recommendation for routine practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23280711" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Utility of subtyping intestinal metaplasia as marker of gastric cancer risk. A review of the evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18424244" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : OLGA staging for gastritis: a tutorial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29875257" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Surveillance of premalignant gastric lesions: a multicentre prospective cohort study from low incidence regions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31816301" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : AGA Technical Review on Gastric Intestinal Metaplasia-Epidemiology and Risk Factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1303129" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Gastric intestinal metaplasia in ethnic groups in the southwestern United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21239166" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : The prevalence of premalignant gastric lesions in asymptomatic patients: predicting the future incidence of gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7735941" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Intestinal metaplasia, atrophic gastritis and stomach cancer: trends over time.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25724703" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Changes in the Gastric Mucosa With Aging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31425693" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Prevalence, risk factors, and surveillance patterns for gastric intestinal metaplasia among patients undergoing upper endoscopy with biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31899705" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Demographic and Lifestyle Risk Factors for Gastric Intestinal Metaplasia Among US Veterans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/49653" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : A model for gastric cancer epidemiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20495574" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Helicobacter pylori: gastric cancer and beyond.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9701005" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Review article: Antioxidant micronutrients and gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26385073" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Pathobiology of Helicobacter pylori-Induced Gastric Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2369748" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Gastric precancerous process in a high risk population: cohort follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22198778" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18395075" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20178099" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Gastric cancer occurrence in preneoplastic lesions: a long-term follow-up in a high-risk area in Spain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26215280" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk Western population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26630310" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Incomplete type of intestinal metaplasia has the highest risk to progress to gastric cancer: results of the Spanish follow-up multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17728213" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Helicobacter pylori cytotoxin-associated genotype and gastric precancerous lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18344895" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Helicobacter pylori infection and development of gastric cancer in Korea: long-term follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27317852" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Risk of Gastric Cancer Among Patients With Intestinal Metaplasia of the Stomach in a US Integrated Health Care System.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27185078" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Risks and Predictors of Gastric Adenocarcinoma in Patients with Gastric Intestinal Metaplasia and Dysplasia: A Population-Based Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26444645" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : The Incidence of Gastric Adenocarcinoma Among Patients With Gastric Intestinal Metaplasia: A Long-term Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1973592" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Intestinal metaplasia and dysplasia in gastric ulcer and its tissue repair.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2083854" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Variants of intestinal metaplasia in the evolution of chronic atrophic gastritis and gastric ulcer. A follow up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1874022" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Subtypes of intestinal metaplasia and gastric carcinoma. A clinicoendoscopic follow-up of 112 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26995689" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Histologic intestinal metaplasia and endoscopic atrophy are predictors of gastric cancer development after Helicobacter pylori eradication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31816300" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : AGA Technical Review on Gastric Intestinal Metaplasia-Natural History and Clinical Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31154030" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Increased Incidence and Mortality of Gastric Cancer in Immigrant Populations from High to Low Regions of Incidence: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17001572" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : A new method of diagnosing gastric intestinal metaplasia: narrow-band imaging with magnifying endoscopy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31816298" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : AGA Clinical Practice Guidelines on Management of Gastric Intestinal Metaplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31529547" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Principles and practice to facilitate complete photodocumentation of the upper gastrointestinal tract: World Endoscopy Organization position statement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Lysosomal hydrolases of the epidermis. I. Glycosidases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30998518" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Early Gastric Cancer: Current Limitations and What Can Be Done to Address Them.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27747283" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Effectiveness of systematic alphanumeric coded endoscopy for diagnosis of gastric intraepithelial neoplasia in a low socioeconomic population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24714327" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : The endoscopic diagnosis of early gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2227346" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Endoscopic diagnosis of intestinal metaplasia
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7875496" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Gastroscopy is incomplete without biopsy: clinical relevance of distinguishing gastropathy from gastritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14606018" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Relationship of gastroscopic features to histological findings in gastritis and Helicobacter pylori infection in a general population sample.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8566631" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Interobserver agreement and predictive value of endoscopic findings for H. pylori and gastritis in normal volunteers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19191891" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Comparison of high resolution magnifying endoscopy and standard videoendoscopy for the diagnosis of Helicobacter pylori gastritis in routine clinical practice: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17273960" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : High-resolution magnification endoscopy can reliably identify normal gastric mucosa, Helicobacter pylori-associated gastritis, and gastric atrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19386303" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Gastric mucosal pattern by using magnifying narrow-band imaging endoscopy clearly distinguishes histological and serological severity of chronic gastritis
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20598685" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Magnifying endoscopy with narrow-band imaging achieves superior accuracy in the differential diagnosis of superficial gastric lesions identified with white-light endoscopy: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20393882" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Narrow band imaging for the detection of gastric intestinal metaplasia and dysplasia during surveillance endoscopy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29449092" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Efficacy of narrow-band imaging for detecting intestinal metaplasia in adult patients with symptoms of dyspepsia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30577062" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Endoscopic grading of gastric intestinal metaplasia (EGGIM): a multicenter validation study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28366441" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Narrow-band imaging versus white light versus mapping biopsy for gastric intestinal metaplasia: a prospective blinded trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22294194" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : A multicenter validation of an endoscopic classification with narrow band imaging for gastric precancerous and cancerous lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23674874" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Narrow-band imaging with magnifying endoscopy is accurate for detecting gastric intestinal metaplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9923930" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Evaluation of gastric mucosal biopsy site and number for identification of Helicobacter pylori or intestinal metaplasia: role of the Sydney System.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12605363" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Diagnostic yield of gastric biopsy specimens when screening for preneoplastic lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15933925" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : The clinical value of taking routine biopsies from the incisura angularis during gastroscopy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20633186" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Biopsy strategies for endoscopic surveillance of pre-malignant gastric lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1842372" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Gastric epithelial dysplasia: a prospective multicenter follow-up study from the Interdisciplinary Group on Gastric Epithelial Dysplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9576449" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Biopsy sites suitable for the diagnosis of Helicobacter pylori infection and the assessment of the extent of atrophic gastritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31788545" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Where should gastric biopsies be performed when areas of intestinal metaplasia are observed?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31700545" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Linked color imaging for the detection of early gastrointestinal neoplasms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31680561" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Reliability and accuracy of blue light imaging for staging of intestinal metaplasia in the stomach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23811245" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Advanced endoscopic imaging: a review of commercially available technologies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23473002" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : The accuracy of probe-based confocal endomicroscopy versus conventional endoscopic biopsies for the diagnosis of superficial gastric neoplasia (with videos).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23189218" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Role of digital chromoendoscopy and confocal laser endomicroscopy for gastric intestinal metaplasia and cancer surveillance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12665759" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Magnification chromoendoscopy for the diagnosis of gastric intestinal metaplasia and dysplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18178207" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : External validation of a classification for methylene blue magnification chromoendoscopy in premalignant gastric lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15333273" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26556485" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Significance of Serum Pepsinogens as a Biomarker for Gastric Cancer and Atrophic Gastritis Screening: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25314140" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Prediction of gastric cancer development by serum pepsinogen test and Helicobacter pylori seropositivity in Eastern Asians: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26789514" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Gastric Cancer Screening by Combined Assay for Serum Anti-Helicobacter pylori IgG Antibody and Serum Pepsinogen Levels--The ABC Method.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27265836" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Combination of Helicobacter pylori Antibody and Serum Pepsinogen as a Good Predictive Tool of Gastric Cancer Incidence: 20-Year Prospective Data From the Hisayama Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28782119" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Systematic review with meta-analysis: diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30841008" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31278206" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31887261" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Histologic Subtyping of Gastric Intestinal Metaplasia: Overview and Considerations for Clinical Practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35337856" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : AGA Institute Quality Measure Development for the Management of Gastric Intestinal Metaplasia With Helicobacter pylori.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17559360" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Helicobacter pylori eradication improves gastric histology and decreases serum gastrin, pepsinogen I and pepsinogen II levels in patients with duodenal ulcer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17991174" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18321787" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Effect of eradication of Helicobacter pylori on the histology and cellular phenotype of gastric intestinal metaplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26198377" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Helicobacter pylori eradication for the prevention of gastric neoplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21282951" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28647684" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Dynamics of Helicobacter pylori infection as a determinant of progression of gastric precancerous lesions: 16-year follow-up of an eradication trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18675689" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29562147" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11839718" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : The long term results of endoscopic surveillance of premalignant gastric lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1955163" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Detection of an increased incidence of early gastric cancer in patients with intestinal metaplasia type III who are closely followed up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24062262" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Surveillance of gastric intestinal metaplasia for the prevention of gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27148773" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Missing rate for gastric cancer during upper gastrointestinal endoscopy: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25117772" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Longer examination time improves detection of gastric cancer during diagnostic upper gastrointestinal endoscopy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20386312" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Meta-analysis on the relationship between nonsteroidal anti-inflammatory drug use and gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14652240" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17270001" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Chronic celecoxib users more often show regression of gastric intestinal metaplasia after Helicobacter pylori eradication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19793174" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Short-term celecoxib to regress long-term persistent gastric intestinal metaplasia after Helicobacter pylori eradication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19522023" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Anti-Helicobacter pylori therapy followed by celecoxib on progression of gastric precancerous lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15985559" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Long term follow up of patients treated for Helicobacter pylori infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16899628" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Effects of long-term rofecoxib on gastric intestinal metaplasia: results of a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17227997" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Chemoprevention of precancerous gastric lesions with antioxidant vitamin supplementation: a randomized trial in a high-risk population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16849680" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11106679" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-helicobacter pylori therapy.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
